Capecitabine and Oxaliplatin Before, During, and After Radiotherapy for High-Risk Rectal Cancer

This aggressive approach with capecitabine and oxaliplatin before, during, and after radiotherapy for high-risk rectal cancer is safe and feasible; it also has an impressive response rate as measured by MRI and a promising 5-year overall survival.